The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...

Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...

Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...

The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.

The first sa-mRNA vaccine to reach any market was Gennova Biopharmaceuticals' Gemcovac, which was launched in India in 2022 ...

Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...

Laura is an editor and staff writer at IFLScience. She obtained her Master's in Experimental Neuroscience from Imperial College London.

Follow the latest COVID-19 Vaccine news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to COVID-19 Vaccine notifications.

Is the COVID-19 vaccine safe and effective for infants and young children? Here's what parents need to know about vaccinating their babies and toddlers against COVID-19.

Findings indicate a sharp drop in immunity after Omicron infection, stressing the necessity for updated vaccines to enhance ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...